A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer. Issue 2 (December 2015) - Baughman, Jan; Loo, Deryk; Chen, Francine; Moore, Paul; Bonvini, Ezio; Vasselli, James; Wigginton, Jon; Cohen, Roger